Antibody-drug conjugates (ADCs) are a cutting-edge class of biopharmaceutical drugs that combine monoclonal antibodies (mABs) with cytotoxic drugs for targeted therapy. Analysis of patents, patent trends, and related literature indicates that ADCs are a highly impactful innovation in the medium-term. This innovation is primarily driven by major pharmaceutical companies, which account for 37% of all patents. The commercial impact is evident from a robust drug pipeline, recent global drug approvals, and various investment activities such as mergers and acquisitions, corporate venture funding, and licensing agreements.

Patenting trends experienced a significant increase in 2017 and have continued to grow since then. While oncology remains the dominant indication, there is a noticeable rise in new therapy areas such as autoimmune diseases and infectious diseases, potentially leading to the entry of new players into the market. The United States remains the leading geography for ADC innovation, closely followed by China.

The innovation landscape is highly competitive, with over 100 public companies identified. Leading patent filers include Roche, Seagen (Pfizer), AstraZeneca, and Abbvie. Among big pharma companies, Daiichi Sankyo, AstraZeneca, and Abbvie have the strongest patent portfolios. In China, Jiangsu Hengrui, Biocytogen, and GeneQuantum lead among the 30+ companies in the space.

There are over 70 startups and small biotech companies in the ADC space, with nearly a quarter of them based in China. GeneQuantum, Oncomatryx, Glykos, and DAC Biotech are leading in terms of patent volumes among startups.

The Antibody Drug Conjugate drug landscape includes 1,172 drugs, primarily focused on oncology (94%) and immunology (1.8%) therapies. The most common route of administration is intravenous. Companies like Biocytogen Pharmaceuticals (Beijing) Co Ltd and Hangzhou DAC Biotech Co Ltd are at the forefront of drug development, particularly in preclinical and Phase II trials. The concentration of drugs in Phase I and Phase II suggests a maturing pipeline with potential market entry in the near future.

There have been 2,847 clinical trials for Antibody Drug Conjugate drugs, with Pfizer and Daiichi Sankyo leading as top sponsors. Oncology trials dominate, with Hodgkin Lymphoma being the top indication. In terms of deals, there have been 809 deals totaling US$227 billion, with the United States leading in both deal volume and value. The market saw a decline in deals from 2020-2022, followed by a slight increase in 2023, indicating market adjustments and strategic consolidations.

Scope

Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.

Key player: This represents a sample list of key players in each use case highlighted in the report.

Startups: This represents a sample list of emerging starups in each use case highlighted in the report.

University: This represents a sample list of leading universities in each use case highlighted in the report.

Key Highlights

1. Antibody Drug Conjugate report is a high-impact innovation area in the Pharma industry, with a growing number of patents being filed and a focus on new indications such as Oncology and Autoimmune Diseases.

2. Big pharma companies like Roche dominate the patent activity in Antibody Drug Conjugate with a dip in new companies filing patents in recent years.

3. Competitive intelligence shows that Merck and seagen in terms of portfolio size are among the leaders with strong innovation portfolios in Antibody Drug Conjugate.

4. The drug landscape for Antibody Drug Conjugate is dominated by innovator drugs, with a focus on Infectious Disease and Immunology, and major players like Biocytogen Pharma and Hangzhou Biotech leading in drug development.

5. Clinical trials in Antibody Drug Conjugate are dominated by Immunology trials, with the Pfizer Inc and Daiichi Sankyo Ltd leading in the number of trials.

Reasons to Buy

Accelerate Innovation with Our Antibody-Drug Conjugates Report:

Emerging technologies like antibody-drug conjugates (ADCs) are transforming the biotech and pharmaceutical landscape. Our comprehensive report delivers critical insights into the latest research, patents, clinical trials, and market trends, empowering strategic decision-making. Gain a competitive edge with data on leading pharma companies, startups, and academic institutions, helping you identify growth opportunities and potential threats. The report also highlights regulatory and compliance developments, essential for navigating complex healthcare frameworks. Whether optimizing R&D strategies or uncovering market opportunities, this report is an invaluable resource for making informed, data-driven decisions in today’s fast-evolving therapeutic landscape